Arctoris announced the appointment of Professor John Mattick AO FAA FTSE FAHMS FRSN HonFRCPA GAICD as a Member of the Board of Directors, and Daniel Thomas PhD LCGI as Head of Discovery Biology. Arctoris is strengthening its senior team while the company is growing its commercial operations and service portfolio to enable more customers to rapidly reach their next drug discovery milestone.
“I am delighted to welcome Professor Mattick and Daniel Thomas to our senior team,” Martin-Immanuel Bittner MD DPhil, Chief Executive Officer and Co-Founder of Arctoris, said. “Their depth of expertise and experience will enable us to further develop our revolutionary drug discovery platform for customers and partners around the world. I look forward to working closely with them to enhance our novel capabilities and services.”
As the former Chief Executive Officer of Genomics England and the former Executive Director of the Garvan Institute of Medical Research in Sydney, Professor Mattick is an expert on how the power of technological advances can transform the discovery and delivery of new therapeutic approaches. He has published over 300 research articles and reviews, which have been cited over 64,000 times, and has received numerous awards for his contributions to the field of molecular biology. With this significant scientific and strategic insight, his appointment to the board of Arctoris will support the development of the company’s pre-optimised and fully validated research and development processes.
"I am delighted to join the Board of Directors of Arctoris. Its fully automated platform allows access to a wide range of methods and technologies, new levels of reproducibility, and exceptional data capture and integration capabilities that are unavailable elsewhere, which will transform biomedical research and drug discovery," said Professor John Mattick.
Daniel Thomas joins Arctoris with more than 20 years’ experience working in early-stage small molecule drug discovery with GlaxoSmithKline. He brings with him an extensive theoretical and practical knowledge of assay development and mechanistic profiling together with an accomplished leadership track record developing trans-national matrix research teams. He also has significant experience in the implementation of transformative technologies and the delivery of key mechanistic data across a broad range of therapeutic areas.
“Generating high-quality, reproducible data while balancing cost, scale and complexity is a fundamental challenge faced by the global drug discovery community today,” Thomas said. “Having experienced these pressures first-hand, I am committed to helping our customers and partners by configuring, running and monitoring experiments in real-time through Arctoris fully automated drug discovery platform.”